Arcus Biosciences, Inc is a biotechnology business based in the US. Arcus Biosciences shares (RCUS) are listed on the NYSE and all prices are listed in US Dollars. Arcus Biosciences employs 236 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Arcus Biosciences
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RCUS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Arcus Biosciences stock price (NYSE: RCUS)Use our graph to track the performance of RCUS stocks over time.
Arcus Biosciences shares at a glance
|Latest market close||$24.82|
|52-week range||$16.69 - $42.36|
|50-day moving average||$26.78|
|200-day moving average||$31.37|
|Wall St. target price||$54.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.59|
Buy Arcus Biosciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Arcus Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arcus Biosciences price performance over time
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||-8.98%|
|3 months (2021-04-29)||-25.73%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
Arcus Biosciences financials
|Revenue TTM||$85.2 million|
|Gross profit TTM||$-81,831,000|
|Return on assets TTM||-18.96%|
|Return on equity TTM||-41.64%|
|Market capitalisation||$2.3 billion|
TTM: trailing 12 months
Shorting Arcus Biosciences shares
There are currently 6.8 million Arcus Biosciences shares held short by investors – that's known as Arcus Biosciences's "short interest". This figure is 4.6% up from 6.5 million last month.
There are a few different ways that this level of interest in shorting Arcus Biosciences shares can be evaluated.
Arcus Biosciences's "short interest ratio" (SIR)
Arcus Biosciences's "short interest ratio" (SIR) is the quantity of Arcus Biosciences shares currently shorted divided by the average quantity of Arcus Biosciences shares traded daily (recently around 947245.45454545). Arcus Biosciences's SIR currently stands at 7.15. In other words for every 100,000 Arcus Biosciences shares traded daily on the market, roughly 7150 shares are currently held short.
However Arcus Biosciences's short interest can also be evaluated against the total number of Arcus Biosciences shares, or, against the total number of tradable Arcus Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcus Biosciences's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Arcus Biosciences shares in existence, roughly 100 shares are currently held short) or 0.1502% of the tradable shares (for every 100,000 tradable Arcus Biosciences shares, roughly 150 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arcus Biosciences.
Find out more about how you can short Arcus Biosciences stock.
Arcus Biosciences share dividends
We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.
Arcus Biosciences share price volatility
Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $16.69 up to $42.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 1.1509. This would suggest that Arcus Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Arcus Biosciences overview
Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co. , Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer.
Stocks similar to Arcus Biosciences
Arcus Biosciences in the news
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Surges As Executive Transfer Could Signal Deeper Gilead Partnership
Frequently asked questionsWhat percentage of Arcus Biosciences is owned by insiders or institutions?
Currently 36.881% of Arcus Biosciences shares are held by insiders and 58.475% by institutions. How many people work for Arcus Biosciences?
Latest data suggests 236 work at Arcus Biosciences. When does the fiscal year end for Arcus Biosciences?
Arcus Biosciences's fiscal year ends in December. Where is Arcus Biosciences based?
Arcus Biosciences's address is: 3928 Point Eden Way, Hayward, CA, United States, 94545 What is Arcus Biosciences's ISIN number?
Arcus Biosciences's international securities identification number is: US03969F1093 What is Arcus Biosciences's CUSIP number?
Arcus Biosciences's Committee on Uniform Securities Identification Procedures number is: 03969F109
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert